Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BGP Group is a prominent Indian pharmaceutical organization specializing in the extraction and manufacture of high-purity Nicotine and its derivatives for the global Nicotine Replacement Therapy (NRT) market. Established in 1976, the group operates state-of-the-art, USFDA and ANVISA-approved facilities in Gujarat, India, producing a wide range of Active Pharmaceutical Ingredients (APIs) including Nicotine USP/EP, Nicotine Polacrilex, and Nicotine Resinate. The company is a key supplier to multinational pharmaceutical firms, providing essential ingredients for smoking cessation products such as chewing gums, patches, and lozenges. BGP Group is recognized for its expertise in phytoceutical discovery and its commitment to international quality standards, holding WHO-GMP and ISO certifications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BGP Group.